[Ip-health] FT: Gilead in $11.9bn deal for Kite Pharma
james.love at keionline.org
Mon Aug 28 08:00:45 PDT 2017
An important part of the $kite patent porfolio on CAR T that $gild is
trying to buy involves NIH funded patents.
On Mon, Aug 28, 2017 at 9:31 AM, Thiru Balasubramaniam <thiru at keionline.org>
> Gilead in $11.9bn deal for Kite Pharma
> by: James Fontanella-Khan
> Gilead Sciences has reached an $11.9bn agreement to acquire Kite Pharma,
> adding a cutting edge anti-cancer technology to its portfolio.
> The Californian biotech group will pay $180 per share for Kite, it
> announced on Monday.
> Gilead’s agreement, first reported by the Wall Street Journal, represents
> nearly a 30 per cent premium on Kite’s closing price on Friday. Joh
> Gilead chief executive, said: "The acquisition of Kit establishes Gilead as
> a leader in cellular therapy and provides a foundation from which to drive
> continued innovation for people with advanced cancers. We are greatly
> impressed with the Kite team and what they have accomplished, and share
> their belief that cell therapy will be the cornerstone of treating cancer.
> Our similar cultures and histories of driving rapid innovation in order to
> bring more effective and safer products to as many patients as possible
> make this an excellent strategic fit."
> Thiru Balasubramaniam
> Geneva Representative
> Knowledge Ecology International
> 41 22 791 6727
> thiru at keionline.org
> Ip-health mailing list
> Ip-health at lists.keionline.org
James Love. Knowledge Ecology International
KEI DC tel: +1.202.332.2670, US Mobile: +1.202.361.3040, Geneva Mobile:
More information about the Ip-health